Clinical trial · Interventional
Neurofilament Light Protein in Peripheral Blood Used as a Biomarker for Neurotoxicity After Isolated Limb Perfusion.
A Prospective Feasibility Trial Measuring Neurofilament Light Protein in Peripheral Blood as a Biomarker for Neurotoxicity After Isolated Limb Perfusion.
NCT04460053CI-TRIAL-00076428ILP-NfLcompletedN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
A prospective feasibility trial initially including 10 patients to investigate if Neurofilament light protein can be detected in peripheral blood in patients undergoing Isolated Limb Perfusion with chemotherapeutic agents. This biomarker could act as predictive biomarker for neurotoxicity after isolated limb perfusion.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Malignant Melanoma | Melanoma | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Neurofilament light protein measurement in Isolated limb perfused patients | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Neurofilament light protein measurement
- description
- Neurofilament light protein measurements in peripheral blood pre- peri- and postoperatively.
- interventionNames
- Procedure: Neurofilament light protein measurement in Isolated limb perfused patients
Primary outcomes (3)
- measure
- Neurofilament light protein measurement in peripheral blood
- timeFrame
- 1 day postoperatively
- description
- Neurofilament light protein
- measure
- Neurofilament light protein measurement in peripheral blood
- timeFrame
- 3 days postoperatively
- description
- Neurofilament light protein
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: 1. Patient scheduled for treatment with isolated limb perfusion 2. Age over 18 years 3. Signed informed consent Exclusion Criteria: * None
References
Publications (2)
- RESULTCorderfeldt Keiller A, Axelsson M, Bragadottir G, Blennow K, Zetterberg H, Olofsson Bagge R. A prospective feasibility trial exploring novel biomarkers for neurotoxicity after isolated limb perfusion. Perfusion. 2024 Nov;39(8):1657-1666. doi: 10.1177/02676591231213506. Epub 2023 Nov 7. PMID 37933726
- DERIVEDCorderfeldt Keiller A, Holmen A, Hansson C, Ricksten SE, Bragadottir G, Olofsson Bagge R. Non-invasive and invasive measurement of skeletal muscular oxygenation during isolated limb perfusion. Perfusion. 2023 Jul;38(5):1019-1028. doi: 10.1177/02676591221093201. Epub 2022 May 16. PMID 35575302